Alzamend Neuro, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ALZN, updated each market day.
ALZN AI Sentiment
AI sees no strong directional signal for Alzamend Neuro, Inc. Common Stock stock over the next 10 market days.
Prediction date: Aug. 19, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Alzamend Neuro, Inc. Common Stock
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Sector
Exchange
Market Cap
$6,899,796
Cap Tier
Employees
6
Headquarters
ATLANTA, GA
Listed Since
June 15, 2021
Website
ALZN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ALZN Volatility
Alzamend Neuro, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
